The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

The report from techUK welcomes the new Labour government's recognition that "decisive change" – underpinned by digital ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-elect has ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

DXPs can now eliminate swivel chair processes. Commercial organisations can integrate existing systems with a DXP and have ...

The genomic medicine space has seen incredible success, but investors are overlooking it. For once, it’s not efficacy that’s ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

Donald Trump has chosen talk show host and celebrity doctor Dr Mehmet Oz to lead the Centers for Medicare and Medicaid ...

Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes ...